BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

2315

CNE100005D27

Biotechnology & Medical Research

End-of-day quote Hong Kong S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
9.55 ^CNY	+3.80%		-6.56%	-20.28%

May. 06	Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies	CI
Apr. 26	Biocytogen Pharmaceuticals' Loss Narrows in 2023	MT

Biocytogen Pharmaceuticals Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company

December 12, 2023 at 05:45 am EST

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. at its EGM held on December 12, 2023 approved election of Ms. Li Yan as a non-employee representatives supervisor of the Company.

Latest news about Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies	May. 06	CI
Biocytogen Pharmaceuticals' Loss Narrows in 2023	Apr. 26	MT
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	Mar. 25	CI
Biocytogen Pharmaceuticals Co., Ltd Announces Antibody Evaluation and Option Agreement with Gilead Sciences, Inc	Feb. 19	CI
Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics	Jan. 23	CI
Biocytogen Pharmaceuticals Gets License for Radiance Biopharma's Tumor Drug	Jan. 08	MT
Biocytogen Pharmaceuticals Co., Ltd. Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	Jan. 08	CI
Biocytogen Pharmaceuticals Co., Ltd. and CtM Biotech Co., Ltd Achieve Milestone Progress in Co-Developing A TCR-Mimic Antibody-Based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	Dec. 27	CI
Biocytogen Strikes Multi-Target Antibody Deal With Neurocrine Biosciences	Dec. 20	MT
Biocytogen Pharmaceuticals Co., Ltd. Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	Dec. 19	CI
Biocytogen, Ona Therapeutics Sign Agreement for Development of Antibody-Drug Conjugates	Dec. 18	MT
Biocytogen Pharmaceuticals Co., Ltd. Announce an Antibody Evaluation, Option and License Agreement with Ona Therapeutics	Dec. 18	CI
Biocytogen Pharmaceuticals Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company	Dec. 12	CI
Biocytogen Pharmaceuticals Gets US Patent for RenMab Mice	Dec. 05	MT
Biocytogen Pharmaceuticals Adopts RenMice Name for Human Antibody Mice	23-09-14	MT
Biocytogen Pharmaceuticals' RenMice Series-Fully Human Antibody and TCR Mouse Models-Showcase Biocytogen's Capabilities to Innovate the Discovery of Biologic Drugs	23-09-14	CI
Myricx Enters into Antibody License Agreement with Biocytogen Pharmaceuticals Co., Ltd	23-09-07	CI
Biocytogen Pharmaceuticals Co., Ltd. Establishes Two Business Divisions to Distinguish Preclinical Models and Services from Antibody Drug R&D	23-08-30	CI
374,929,920 H Shares of Biocytogen Pharmaceuticals Co., Ltd. are subject to a Lock-Up Agreement Ending on 31-AUG-2023.	23-08-30	CI
Biocytogen Pharmaceuticals' Loss Narrows in H1; Shares Up 12%	23-08-29	MT
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Biocytogen Pharmaceuticals Co., Ltd. Announces Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth	23-08-17	CI
Biocytogen Pharmaceuticals Announces Grand Opening of Waltham, MA Facility	23-08-16	CI
Biocytogen Pharmaceuticals' RenMab Platform Technology Gets Chinese Patent	23-07-11	MT

Chart Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Duration

Period

Chart Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

More charts

Biocytogen Pharmaceuticals Beijing Co Ltd is a company mainly engaged in drug development business and preclinical research. The Company operates its business through five segments. The Gene-Editing services segment provides the customized gene-editing services based on animals as well as cells. The Pre-clinical Pharmacology and Efficacy Evaluation segment provides preclinical pharmacology services for the evaluation of drug efficacy and toxicity. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment utilises its antibody discovery platforms to identify antibodies which have the potential to become drug candidates. The Innovative Drugs Development segment is engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The Company also conducts its business through the Other segment.

Sector

Biotechnology & Medical Research

Calendar

2024-05-27 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.512 CNY

Average target price

14.21 CNY

Spread / Average Target

+66.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.	-20.28%	471M
MODERNA, INC.	+34.11%	50.85B
IQVIA HOLDINGS INC.	+0.70%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.95%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.55%	19.13B
BIO-TECHNE CORPORATION	+9.29%	13.05B
MEDPACE HOLDINGS, INC.	+27.02%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.96%	12.08B

Other Biotechnology & Medical Research

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

Biotechnology & Medical Research

Biocytogen Pharmaceuticals Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company

Latest news about Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Chart Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research